JOP20210168A1 - أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري - Google Patents
أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشريInfo
- Publication number
- JOP20210168A1 JOP20210168A1 JOP/2021/0168A JOP20210168A JOP20210168A1 JO P20210168 A1 JOP20210168 A1 JO P20210168A1 JO P20210168 A JOP20210168 A JO P20210168A JO P20210168 A1 JOP20210168 A1 JO P20210168A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibody
- human
- bind specifically
- cell receptors
- trbv9
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
يتعلق الاختراع بجسم مضاد antibody أحادي النسيلة monoclonal مكتسب السمة البشرية humanized أو شدفة fragment رابطة لمستضد antigen-binding منه والذي يرتبط نوعيًا بعائلة TRBV9 لمستقبل الخلية التائية البشرية T cell receptor (TCR). كما يتعلق الاختراع بحمض نووي nucleic acid يشفر الجسم المضاد المذكور أو شدفة رابطة لمستضد منه، ناقل تعبير expression vector، طريقة لتحضير الجسم المضاد المذكور، واستخدام الجسم المضاد المذكور في معالجة الأمراض أو الاضطرابات المرتبطة بعائلة مستقبل الخلية التائية البشرية. يتم توجيه الاختراع لتوليد الأجسام المضادة التي يمكن استخدامها لعلاج، تحديدًا التهاب الفقرات التصلبي ankylosing spondylitis (AS)، المرض البطني celiac disease وأمراض الدم الخبيثة malignant blood diseases، والتي تنطوي مسبباتها pathogenesis على TCRs لعائلة TRBV9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018146029A RU2711871C1 (ru) | 2018-12-25 | 2018-12-25 | Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения |
PCT/RU2019/050257 WO2020139171A1 (ru) | 2018-12-25 | 2019-12-24 | Моноклональные антитела, специфически связывающиеся с trbv-9 человека |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210168A1 true JOP20210168A1 (ar) | 2023-01-30 |
Family
ID=69184146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0168A JOP20210168A1 (ar) | 2018-12-25 | 2019-12-24 | أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري |
Country Status (24)
Country | Link |
---|---|
US (1) | US20220056133A1 (ar) |
EP (1) | EP3904387A4 (ar) |
KR (1) | KR20210118843A (ar) |
CN (1) | CN113692412A (ar) |
AR (1) | AR117735A1 (ar) |
AU (1) | AU2019416787A1 (ar) |
BR (1) | BR112021012550A2 (ar) |
CA (1) | CA3124800A1 (ar) |
CL (1) | CL2021001704A1 (ar) |
CO (1) | CO2021008204A2 (ar) |
CR (1) | CR20210353A (ar) |
EA (1) | EA202100199A1 (ar) |
EC (1) | ECSP21046332A (ar) |
IL (1) | IL284367A (ar) |
JO (1) | JOP20210168A1 (ar) |
MA (1) | MA53688B1 (ar) |
MX (1) | MX2021007718A (ar) |
PE (1) | PE20211792A1 (ar) |
PH (1) | PH12021551535A1 (ar) |
RU (1) | RU2711871C1 (ar) |
SG (1) | SG11202106974SA (ar) |
TW (1) | TW202033557A (ar) |
WO (1) | WO2020139171A1 (ar) |
ZA (1) | ZA202104356B (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
CN116510006A (zh) * | 2022-01-31 | 2023-08-01 | 拜奥卡德联合股份公司 | 抗trbv9抗体的药物组合物及其用途 |
WO2024039268A1 (ru) * | 2022-08-18 | 2024-02-22 | Акционерное общество "БИОКАД" | Способ лечения заболевания, опосредованного т-лимфоцитами |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
US5223426A (en) | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
EP2298809A3 (en) * | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
EP2446052B1 (en) * | 2009-06-25 | 2018-08-08 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
WO2018090057A1 (en) * | 2016-11-14 | 2018-05-17 | Fred Hutchinson Cancer Research Center | High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof |
US20200040085A1 (en) * | 2017-02-27 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease |
CN107502671B (zh) * | 2017-10-12 | 2020-05-05 | 中国医学科学院肿瘤医院 | 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用 |
RU2694412C9 (ru) | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
-
2018
- 2018-12-25 RU RU2018146029A patent/RU2711871C1/ru active
-
2019
- 2019-12-23 AR ARP190103841A patent/AR117735A1/es unknown
- 2019-12-24 WO PCT/RU2019/050257 patent/WO2020139171A1/ru unknown
- 2019-12-24 CR CR20210353A patent/CR20210353A/es unknown
- 2019-12-24 KR KR1020217023567A patent/KR20210118843A/ko unknown
- 2019-12-24 CN CN201980092914.6A patent/CN113692412A/zh active Pending
- 2019-12-24 EP EP19904442.1A patent/EP3904387A4/en active Pending
- 2019-12-24 CA CA3124800A patent/CA3124800A1/en active Pending
- 2019-12-24 MX MX2021007718A patent/MX2021007718A/es unknown
- 2019-12-24 SG SG11202106974SA patent/SG11202106974SA/en unknown
- 2019-12-24 MA MA53688A patent/MA53688B1/fr unknown
- 2019-12-24 TW TW108147433A patent/TW202033557A/zh unknown
- 2019-12-24 AU AU2019416787A patent/AU2019416787A1/en active Pending
- 2019-12-24 PE PE2021001079A patent/PE20211792A1/es unknown
- 2019-12-24 EA EA202100199A patent/EA202100199A1/ru unknown
- 2019-12-24 JO JOP/2021/0168A patent/JOP20210168A1/ar unknown
- 2019-12-24 US US17/417,570 patent/US20220056133A1/en active Pending
- 2019-12-24 BR BR112021012550-7A patent/BR112021012550A2/pt unknown
-
2021
- 2021-06-23 CO CONC2021/0008204A patent/CO2021008204A2/es unknown
- 2021-06-24 CL CL2021001704A patent/CL2021001704A1/es unknown
- 2021-06-24 IL IL284367A patent/IL284367A/en unknown
- 2021-06-24 EC ECSENADI202146332A patent/ECSP21046332A/es unknown
- 2021-06-24 ZA ZA2021/04356A patent/ZA202104356B/en unknown
- 2021-06-25 PH PH12021551535A patent/PH12021551535A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202104356B (en) | 2022-09-28 |
WO2020139171A1 (ru) | 2020-07-02 |
PH12021551535A1 (en) | 2022-02-28 |
MX2021007718A (es) | 2021-08-05 |
CO2021008204A2 (es) | 2021-08-30 |
SG11202106974SA (en) | 2021-07-29 |
EP3904387A1 (en) | 2021-11-03 |
CL2021001704A1 (es) | 2022-01-28 |
KR20210118843A (ko) | 2021-10-01 |
MA53688B1 (fr) | 2023-03-31 |
AR117735A1 (es) | 2021-08-25 |
BR112021012550A2 (pt) | 2021-09-14 |
CN113692412A (zh) | 2021-11-23 |
EP3904387A4 (en) | 2022-09-07 |
AU2019416787A1 (en) | 2021-08-12 |
ECSP21046332A (es) | 2021-07-30 |
TW202033557A (zh) | 2020-09-16 |
EA202100199A1 (ru) | 2021-12-02 |
CA3124800A1 (en) | 2020-07-02 |
PE20211792A1 (es) | 2021-09-09 |
IL284367A (en) | 2021-08-31 |
MA53688A1 (fr) | 2022-06-30 |
RU2711871C1 (ru) | 2020-01-23 |
JP2022515820A (ja) | 2022-02-22 |
US20220056133A1 (en) | 2022-02-24 |
CR20210353A (es) | 2021-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551535A1 (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
MX2021005193A (es) | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. | |
CO6260105A2 (es) | Anticuerpos humanos contra cd20 humano y metodo para utilizarlos | |
MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
PH12021551532A1 (en) | Monoclonal antibodies against the beta chain region of human trbv9 | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
MX2022012182A (es) | Metodos de uso de anticuerpos anti-trem2. | |
EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
ZA202008095B (en) | Humanized antibodies against psma | |
EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
WO2012170929A3 (en) | Monoclonal antibody and antigens for diagnosing and treating lung disease and injury | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
EA201891800A1 (ru) | Антитела к цитруллинированным hla-полипептидам и их применение | |
MX2022007156A (es) | Metodos de uso de anticuerpos anti-cd33. | |
MX2022008745A (es) | Anticuerpos anti-nkp30 y metodos de uso. | |
ECSP19018367A (es) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 |